# Cell Derivation and Maintenance Core

> **NIH NIH P01** · OHIO STATE UNIVERSITY · 2024 · $329,033

## Abstract

CORE 4 - SUMMARY
COVID-19 remains a worldwide health threat. While some people recover quickly and have mild/no symptoms,
at least one third develop long-term symptoms referred to as Long-COVID. In order to identify new therapeutic
targets this Program will decipher the role of specific pathways and identify the cell-types that control
inflammation and virus virulence. The “Cell Derivation and Maintenance Core” or Core 4 will support this Program
by providing primary human and/or mouse airway epithelial cells, immune cells, endothelial cells, and cells
isolated from the brain. This core will also provide blood as well as fixed brain and lung tissues from patients
non-infected and infected with SARS-CoV-2. This core will support Projects 1-3 and will also provide primary
airway cells to Core 3.

## Key facts

- **NIH application ID:** 10862012
- **Project number:** 1P01AI175399-01A1
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Estelle A Cormet-Boyaka
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $329,033
- **Award type:** 1
- **Project period:** 2024-04-10 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10862012

## Citation

> US National Institutes of Health, RePORTER application 10862012, Cell Derivation and Maintenance Core (1P01AI175399-01A1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10862012. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*